Use of Singulair in asthma
-
Upload
cscoville -
Category
Health & Medicine
-
view
3.191 -
download
4
Transcript of Use of Singulair in asthma
Use of Singulair in AsthmaAda Sum, MD
Case Presentation
9 yo boy presents to clinic to establish care
Hx of asthma and allergic rhinitis Current Rx: Flovent 44mcg 1 puff BID
and albuterol PRNMom asks if he can be switched to
SingulairROS:
Nocturnal cough causing awakening perhaps 1 every other week
Uses albuterol inhaler maybe 3/week
Brief Asthma Review
National Asthma Education and Prevention Program’s Expert Panel Report 3 published in 2007: Asthma severity: severity when initiating
therapy Asthma control: control to adjust therapy▪ Based on impairment and risk
Stepwise approach to managing long-term asthma Separated into ages 0-4, 5-11, & 12 and
up
Stepwise Approach
Inhaled corticosteroids is the preferred long-term control therapy for all ages
Evidence A: randomized controlled trials, rich body of data (NHLBI)
Components of control
Classification of asthma control (5-11 years of age)
Well-controlled
Not-well controlled
Very poorly controlled
Impairment Symptoms ≤2 days/week but not more than once on each day
>2 days/week or multiple times on ≤2 days/week
Throughout the day
Nighttime awakenings
≤1x/month ≥2x/month ≥2x/week
Interference with normal activity
None Some limitation Extremely limited
Short-acting beta2-agonist use for symptom control (not prevention of EIB)
≤2 days/week >2 days/week Several times per day
• FEV1 or peak flow• FEV1/FVC
• >80 percent predicted/personal best• >80 percent
• 60-80 percent predicted/personal best• 75-80 percent
• <60 percent predicted/personal best• <75 percent
Risk Exacerbations requiring oral corticosteroids
0-1/year ≥2/year
Consider severity and interval since last exacerbation
Reduction in lung growth
Evaluation requires long-term followup
Treatment-related adverse effects
Medication side effects can vary in intensity from none to very troublesom and worrisome.
Cysteinyl Leukotrienes
Eosinophils and mast cells produce cysteinyl leukotrienes (CysLT) Synthesized within minutes
CysLTs bind to receptors CysLT1 and CysLT2
CysLT1 receptor mediates: Induce smooth muscle
contraction and sustained bronchoconstriction▪ “slow reacting substance of
anaphylaxis” Mucus secretion Edema
CysLTs and Asthma
Asthmatics have higher baseline levels of CysLTs
Levels increase with exercise, exposure to allergens, and during exacerbations
Singulair (montelukast) and Accolate (zafirlukast): CysLT1 receptor
antagonists
Singulair
Chewable (30): $138.97Common side effects:
URI, fever, HA, pharyngitis, cough, abdominal pain, diarrhea, otitis media, flu, rhinorrhea, sinusitis, otitis
FDA warning: neuropsychiatric events Agitation, aggression, depression,
suicide, abnormal dreams, insomnia, hallucinations, irritability, tremor were reported in both kids and adults
Clinical Question
How does the addition of a leukotriene receptor antagonist to low-dose inhaled corticosteroids change the asthma control in children with poorly-controlled asthma, as compared to medium-dose inhaled corticosteroids?
Population: children with poorly-controlled asthma on low-dose inhaled corticosteroids
Intervention: leukotriene receptor antagonist + low-dose inhaled corticosteroids
Comparison: medium-dose inhaled corticosteroids
Outcome: change in asthma control
Search Efforts
Medline searchMeSH terms:
Asthma “Singulair” keyword = montelukast
leukotriene receptor antagonistsLimits:
Kids English Randomized controlled trials
Article Chosen
BADGER trial
Best Add-on Therapy Giving Effective Responses
Looking for differential response Three-way crossover design Based on composite of outcomes:▪ Asthma exacerbations▪ Asthma-control days▪ FEV1
Examined potential predictors: Race, age, genotype, baseline values
Study Design
Run-in Period
To determine whether asthma poorly-controlled on fluticasone 100 mcg BID
Daily diaryUncontrolled if during a 2-week
period, had >2 days/week of: Moderate or severe coughing Mild, moderate, or severe wheezing ≥2 puffs/day of rescue inhaler Peak flows <80% predicted
Crossover Trial
Randomized and double-blinded Placebo tablets Dummy disks
16 week periods: Flovent 250 mcg BID Advair (fluticasone 100 mcg +
salmeterol 50 mcg) BID Flovent 100 mcg BID + Singulair (5 or 10
mg) daily Initial 4 weeks considered active
washout
Asthma Action Plan
Customized written action planVisits every 4 weeksReceived albuterol inhalerStandardized course of prednisone
was initiated if predetermined clinical criteria met at the physician’s discretion
Outcome Measures
Based on composite of: Need for treatment with oral prednisone
for acute asthma exacerbation Number of asthma-control days FEV1
Treatment period ranked better if: Total prednisone during period 180mg
less Annualized asthma-control days 31 days
more Final FEV1 5% higher
Asthma-Control Day
Documented in diary No use of albuterol (other than
preexercise) No use of nonstudy asthma medication No day or night asthma symptoms No unscheduled visit to health care
provider for asthma No peak expiratory flow <80%
Proportion during the 12 weeks x 365 = annualized asthma-control days Adjusted for seasonal differences
Recruitment
March 2007 to July 2008Patients aged 6-17Childhood Asthma Research and
Education (CARE) Network Centers: National Jewish Health University of Wisconsin University of California San Diego Washington University School of Medicine Arizona Respiratory Center
480 enrolled
Inclusion Criteria
Mild to moderate asthmaAbility to perform reproducible
spirometryFEV1 ≥ 60% before bronchodilation Increase in FEV1 of at least 12% or
methacholine provocation causing a 20% fall
Nonsmoker
Patients
298 patients excluded during run-in period Compliance issues Asthma exacerbation Asthma symptoms controlled
182 underwent randomization157 patients completed the entire
study 90% adherence to study visits 96% adherence to paper diary 84% adherence to study tablets (electronic cap
monitor) 87% adherence to study inhalers (disk counter)
Patient Population
Age GroupCharacteristic 6-11 yr (n = 126) 12-17 yr (n = 56)
Age 9.1 ± 1.5 14.7 ± 1.7 Male 83 (66) 36 (64) Race Hispanic or Latino Non-Hispanic White Black Hispanic White
38 (30)54 (43)37 (29)28 (22)
22 (39)20 (36)12 (21)15 (27)
BMI 19.6 ± 4.5 23.3 ± 4.8 Age at asthma diagnosis 3.3 ± 2.2 4.7 ± 4.1 Eczema 69 (55) 24 (43) Eligibility Classification Step-up Step-neutral Step-down
35 (28)16 (13)75 (60)
14 (25)11 (20)31 (55)
PO steroids in past year 56 (44) 24 (45) Asthma Control Test (≤19) 20.5 ± 3.8 19.8 ± 3.4
Data
Null hypothesis: ≤25% of patients would have a
differential response If significant response (0.01 level),
then perform logistic regression to determine whether 4 preselected characteristics predicted differential responses
Differential response in 161/165 patients (98%)
Results
52% vs 34%, P=0.02
54% vs 32%, P=0.004
LABA on Top
LABA vs LTRA: relative probability 1.6 (CI 1.1-2.3, P=0.004)
LABA vs ICS: relative probability 1.7 (CI 1.2-2.4, P=0.002)
Preselected Predictors
P=0.009
Race (P=0.005)
Eczema (P=0.006)
Age (no difference)
Also no difference for genderA model with only the significant
predictors, correctly classified the ranks 68% of the time
Conclusion
Possible ceiling effect for ICS Addition of LABA more likely to provide better
asthma control But some children had best response to the other step-
up therapies Increasing ICS dosage is similar to addition of
LTRA
Study does NOT address long-term safety of LABAs Potential increased risk of severe exacerbations and
death Never to be used as monotherapy FDA label: discontinue LABA when possible
Validity
PROS
Adequate power Double blinded Randomized Kids Diverse population Decent adherence Individuals vs average
CONCERNS
No placebo or gold standard
Increased monitoring by participating in study
Medications donated Physician consulting
fees, lecture fees, grants by pharmaceutical companies
Answering Mom
Switch to Singulair? No!
Patient currently poorly controlled on low-dose ICS Needs step up in therapy
One of several options to discuss with Mom LABA, medium-dose ICS, or LTRA Other factors: race, history of eczema
Need to reassess control and follow-up
Application
The secret of the care of the patient is in caring for the patient.
-Francis Weld Peabody
References
Von Mutius, E and JM Drazen. “Choosing asthma step-up care.” N Eng J Med. 362(11): 1042-1043.
Lemanske, RF, et al. “Step-up therapy for children with uncontrolled asthma receiving inhaled steroids.” N Eng J Med. 362(11): 975-985, 2010.
National Asthma Education and Prevention Program. “Expert panel report 3 (ERP-3) summary report 2007: Guidelines for the diagnosis and management of asthma.” 2007. Accessed online: http://www.nhlbi.nih.gov/guidelines/asthma/asthsumm.pdf.
Weinberger, MM. “Use of LABAs in asthmatic children requires close monitoring.” AAP News. 31(9): 20, 2010.
Databases: Clinical Evidence, Dynamed, Medline, UpToDate.
Google images.